Hodgkin’s lymphoma (LH) relapse-refractory (R / R) in Pediatrics: how do we incorporate the new therapies?
Vol. 22 No. Extraordin (2018), Pediatric Hematology
Vol. 22 No. Extraordin (2018)

Hodgkin’s lymphoma (LH) relapse-refractory (R / R) in Pediatrics: how do we incorporate the new therapies?

Pediatric Hematology
Published 2019-01-21
DA Veron
Servicio de Hematología y Oncología Pediátrica. Hospital Universitario Austral. Pilar, Buenos Aires, Argentina.
ISSN 2250-8309 (versión en línea) - ISSN 0329-0379 (versión impresa)
pdf (Español (España))

Keywords

pediatric Hodgkin lymphoma, refractory-relapsed pediatric Hodgkin lymphoma

How to Cite

Veron, D. (2019). Hodgkin’s lymphoma (LH) relapse-refractory (R / R) in Pediatrics: how do we incorporate the new therapies?. Journal of Hematology, 22(Extraordin), 72–78. Retrieved from https://www.revistahematologia.com.ar/index.php/Revista/article/view/58
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Despite the advances made in the treatment of Hodgkin’s lymphoma in pediatrics, we know that a percentage of patients, increasingly smaller due to the intensity of first-line treatments, will behave as refractory to treatment or relapse in a variable time.

However, in view of the changes that have occurred in recent years in first-line therapy and in the tools available for the rescue of these patients, this scenario deserves to be discussed and redefined.

pdf (Español (España))

References

1. Schellong et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. JCO. 2005 Sep 1;23(25):6181-9.
2. Shankar et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. BJH. 2014 May;165(4):534-44.
3. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. BMT. 2008 Oct;42 Suppl 2: S16-24.
4. Harker-Murray P et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. PBC. 2014 Apr;61(4):579-86.
5. Satwani et al. A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma. BMT. 2015 Nov; 50(11): 1416–1423.
6. Gayoso J et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. JCO. 2017 Oct 20;35(30):3425-3432.
7. Moskowitz et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62.
8. Cole P, Schwartz CL, Drachtman R, de Alarcón P, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a COG report. J Clin Oncol. 2009 Mar 20; 27(9): 1456-61.
9. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010 Aug;16(8):1145-54.
10. Cole P, McCarten K, Drachtman R, de Alarcon P, Chen L, Trippett T and Schwartz CL.Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine for Refractory Hodgkin Disease: A Children’s Oncology Group Report. Pediatr Hematol Oncol. 2010 November; 27(8): 650–657.
11. Santoro A, Magagnoli M, SpinaM, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Hematologica. 2007 Jan;92(1):35-41.
12. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5.
13. Locatelli et al. Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. Blood. 2013 122:4378.
14. Cheson et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 128: 2489-2496.

All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar

Downloads

Download data is not yet available.